Celgene Announces Deal with Jounce to Develop Cancer Drug

Jul 20, 2016

The Boston Globe

Celgene will offer a $225 million upfront payment to Jounce Therapeutics to develop cancer drugs, according to an article in The Boston Globe. The agreement, which could be worth as much as $2.3 billion, will fund a new type of drug that stimulates the immune system to fight tumors.

Celgene will take a $36 million equity stake in Jounce, and will share profits and losses from its experimental drug, JTX-2011. Read the full story

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments